High Times
Home > Boards > US OTC > Cannabis >

CV Sciences Inc. (CVSI)

Add CVSI Price Alert      Hide Sticky   Hide Intro
Moderator: lester12483, AsiaT, PennystockID2017, ANIA77, Sunblazers, Benjamin Wulf
Search This Board: 
Last Post: 10/20/2018 1:35:50 PM - Followers: 513 - Board type: Free - Posts Today: 10

CV Sciences United States OTCMKTS:CVSI Business Cannabidiol - united states

CV Sciences, Inc., incorporated on July 26, 2013, is a life science company. The Company operates in two segments: specialty pharmaceuticals and consumer products. The Company’s specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol (CBD) across several therapeutic areas. The consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.


The Company's product candidates utilize synthetic CBD as the active pharmaceutical ingredient. Its product candidates are in preclinical studies. The Company manufactures, markets and sells products containing hemp-derived CBD primarily under its PlusCBD brand. The Company's subsidiaries include US Hemp Oil, LLC, CannaVest Laboratories, LLC, Plus CBD, LLC and CannaVest Europe, GmbH.

The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant-based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction. The market for cessation of smokeless tobacco use and addiction is estimated at $2 billion, growing to over $4 billion in the next 5-6 years.


CV Sciences, Inc. Issues Letter to Shareholders

GlobeNewswireJune 27, 2018

LAS VEGAS, June 27, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc., (CVSI) (the "Company," "CV Sciences," "our" or "we"), preeminent manufacturer and distributor of the industry-dominating brand of hemp extract products, PlusCBD Oil™, announced today that it has issued a letter to its shareholders, providing an update on the Company’s recent progress and upcoming objectives. 

Highlights of the Letter Include:

  • Summary of its record breaking and profitable first quarter of 2018 which included record revenue, gross profit, cash flow, adjusted EBITDA and net income.
    Expansion of the Company’s footprint in the CBD product market with its PlusCBD Oil™ hemp-based CBD products rated #1 in the natural products retailer sales channel.  This market opportunity is forecasted at $2.5 billion by 2022.
    Updates on its drug development efforts, its proprietary patent-pending drug candidate (CVSI-007) to treat smokeless tobacco addiction, a $2 billion market opportunity.
    Corporate developments that include deleveraging the Company’s balance sheet and positioning for future growth.
    Details of CV Sciences’ upcoming annual general meeting (AGM) to be held on August 4, 2018 at the Company’s new San Diego headquarters.
    Initiatives for 2018, focusing on operational efficiencies, sales growth, distribution channels, large drug development milestones that include investigational new drug application submission and clinical trials, and uplisting our stock to a major national exchange.

The Company’s Chief Executive Officer, Joseph Dowling, commented, “Our uplist initiative to a major national exchange is an important Company objective. The national exchanges require that a listed company’s stock price trade at certain levels for acceptance. We have included a proposal for shareholder vote at our AGM on August 4, 2018 for a reverse stock split, which has as its sole purpose clearing a pathway for the Company to “uplist” to a major national exchange. The Company will effectuate the reverse split only in connection with an application to uplist to a major exchange, and only if necessary.”  

To read the Letter to Shareholders in full, please visit: https://ir.cvsciences.com

About CV Sciences, Inc.

CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.


Robert Haag
Managing Director
IRTH Communications


The Company competes with GW Pharmaceuticals, PLC, Zynerba Pharmaceuticals Inc. and Insys Therapeutics Inc


CV Sciences, Inc. Announces Landmark Publication on the Toxicology and Safety Assessment of Base Material of its PlusCBD Oil™ Products

GlobeNewswireJune 15, 2018

LAS VEGAS, June 15, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our” or “we”) announced today the June 7, 2018 publication of the toxicology and safety results of an extract from the base raw materials used in its market leading PlusCBD Oil™ consumer products. The Company contracted respected scientific and regulatory consulting firm, AIBMR Life Sciences, Inc, to conduct the battery of toxicological studies to investigate the safety of oral consumption of the Company’s hemp cannabidiol (CBD) oil and to support a Generally Recognized as Safe (GRAS) Independent Conclusion.

The monumental study entitled, “An Assessment of the Genotoxicity and Subchronic Toxicity of a Subcritical Fluid Extract of the Aerial Parts of Hemp”concluded that the test article was non-mutagenic, non-clastogenic and non-genotoxic. The toxicological assessment is the first known published data of its kind since the 1980 Rosenkrantz et al.’s publication with respect to toxicology data on CBD, Cannabichromene and hashish oil. The battery of GLP/OECD compliant studies is a major contribution in advancement of the science of hemp-derived CBD.

The investment in this toxicological assessment demonstrates CV Sciences’ commitment in furthering the science behind the ingredient. AIBMR’s Chief Scientific Officer, John Endres, ND, comments, “Until today, there have been no comprehensive toxicological safety assessments completed on hemp CBD oil for 38 years. The completion and publication of these safety studies on this ingredient in a peer-reviewed academic journal specializing in toxicology is a monumental step forward in putting competent and reliable science behind a product. The public should applaud this effort as well as the time and expense it required.”

The Company’s Chief Executive Officer, Joseph Dowling, echoed this sentiment. “We are thrilled to advance phytocannabinoid science and are very pleased with the safety results from this landmark study. This is an important milestone in our pursuit of GRAS status,” he remarked. “As an organization, our commitment to safety remains paramount. We look forward to setting the bar for all hemp extract manufacturers in the market and encourage them to conduct similar toxicological assessments on their own base raw materials.”

About CV Sciences, Inc.
CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

Video tour of San Diego Office of CVSI.

High Times
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
#28502   Key talking points: Deetew 09/29/18 05:09:57 PM
#27902  Sticky Note Fantastic report. Must read. https://www.streetwisereports.com/article/2018/09/ Emerald77 09/24/18 07:39:45 PM
#20309  Sticky Note Please read this BOARD WARNING before you submit IH Admin [Tisha] 08/22/18 12:47:06 PM
#30874   This company is killing it baldingcontrarian 10/20/18 01:35:50 PM
#30873   That may be the best summary of reason mc73 10/20/18 01:34:34 PM
#30872   What did famous stock trader Jesse Livermore say? baldingcontrarian 10/20/18 01:31:44 PM
#30871   Your broken record of I-Glow like statements is MartyTamreau 10/20/18 12:39:45 PM
#30870   Yes that will be here fast, strong earnings Alwaysbmikki 10/20/18 11:27:07 AM
#30869   The fake lawsuits should all be coming to pauly3 10/20/18 10:29:06 AM
#30868   Last qt report came out 8-1-18. Third pauly3 10/20/18 10:15:28 AM
#30867   Look at the yellow sticky above mc73 10/20/18 02:23:06 AM
#30866   Nice gaslighting...been at it long? mc73 10/20/18 02:21:56 AM
#30865   Any help? Looking to add to my $VATE$. japeterson 10/20/18 01:30:26 AM
#30864   I have to hand it to BKK. He Chirodoctor 10/19/18 11:19:44 PM
#30861   I thought long and hard about your reply microcappatty 10/19/18 08:42:44 PM
#30860   Here's one for ya! And none of these ap17 10/19/18 08:26:03 PM
#30859   Who hear thinks BKK sounds just like I-Glow playofthedivine 10/19/18 07:55:53 PM
#30858   No disagreement here. I will love it when Chirodoctor 10/19/18 07:18:19 PM
#30857   Access to capital ??? baldingcontrarian 10/19/18 07:15:19 PM
#30856   That’s not slander baldingcontrarian 10/19/18 07:12:30 PM
#30855   we are in earnings season You are correct Kswies 10/19/18 07:07:01 PM
#30854   ZERO DEBT, NET PROFITABLE!! mc73 10/19/18 06:56:53 PM
#30853   These companies pay money to these publishers to SweetEquity 10/19/18 06:41:16 PM
#30852   What is the average quarterly profit at this Natureboy1 10/19/18 06:39:12 PM
#30851   How much debt does CVSI currently have? Anyone? Natureboy1 10/19/18 06:38:28 PM
#30850   I agree, but wouldn't use the expression - SweetEquity 10/19/18 06:33:52 PM
#30849   Benefits of Up-listing From OTC to Nasdaq and SweetEquity 10/19/18 06:23:34 PM
#30848   Top 10? BadKarmaKyle 10/19/18 06:18:27 PM
#30847   Each persons reality is in the perception of Chirodoctor 10/19/18 06:16:42 PM
#30845   You could use some PlusCBD. It's good stuff. FastMny 10/19/18 06:05:19 PM
#30844   Dude you have one person following you after baldingcontrarian 10/19/18 06:04:57 PM
#30843   Low volume, in the red and THIS ticker BadKarmaKyle 10/19/18 06:03:11 PM
#30842   A 505(B)(2) Drug Dev.Cost - Greater than 100 SweetEquity 10/19/18 05:58:53 PM
#30841   You are comparing the perception of disasterous lawsuits, Chirodoctor 10/19/18 05:56:54 PM
#30840   I am hoping for the uplist too! Actually mc73 10/19/18 05:39:59 PM
#30839   Sorry but the Uplist will be grantedI hope Kswies 10/19/18 05:35:11 PM
#30838   Yes as stated months ago baldingcontrarian 10/19/18 05:15:13 PM
#30837   It will run up with Q report but mc73 10/19/18 04:31:18 PM
#30836   The exchange is equal blame for the citron ap17 10/19/18 04:30:12 PM
#30835   Average cost of clinical trials is $18M. How mc73 10/19/18 04:29:51 PM
#30834   Sure, it may go south... temporarily— thats just microcappatty 10/19/18 04:26:04 PM
#30833   We will have to agree to disagree, I Kswies 10/19/18 04:19:45 PM
#30832   Agree 100% - I'm secretly hoping for that. mc73 10/19/18 04:19:08 PM
#30831   Agreed! That would be the ultimate move capital wise. ap17 10/19/18 04:18:45 PM
#30830   I could give a rats you know what playofthedivine 10/19/18 04:17:56 PM
#30829   The current sp is about being the #1 microcappatty 10/19/18 04:14:51 PM
#30828   CBD is entering main stream , all I Alwaysbmikki 10/19/18 04:07:31 PM
#30827   Stop speculating the worst????? Plan for the worst Kswies 10/19/18 03:56:34 PM
#30826   Exactly! Thanks hmmmmmm for articulating the real reason playofthedivine 10/19/18 03:53:05 PM
#30825   Just concerned is all. I've made a lot Kswies 10/19/18 03:52:50 PM
#30824   You are free to disagree. microcappatty 10/19/18 03:48:07 PM
#30823   I'm would think a patented formulation with CBD, SweetEquity 10/19/18 03:42:15 PM
#30822   Correct me if im wrong..but the uplist news Hmmmmmm 10/19/18 03:38:53 PM